Free Fatty Acids Induce Peripheral Insulin Resistance Without Increasing Muscle Hexosamine Pathway Product Levels in Rats
Article Figures & Tables
Figures
- FIG. 1.
Plasma insulin (A), glucose (B), and FFA (C) concentrations and GINF (D) during the 480-min hyperinsulinemic-euglycemic clamp with an infusion of saline (○), Intralipid (□), glucosamine (•), or Intralipid and glucosamine (▪) that was initiated at 150 min as indicated by broken lines. Values are means ± SE for eight or nine experiments.
- FIG. 2.
GINF (A), insulin-stimulated Rd (B), and HGO (C) during the final 30 min of the control (120-150 min [□]) and the treatment (450-480 min [cjs2113]) periods in the saline, Intralipid (IL), glucosamine (GN), and Intralipid + glucosamine (IL+GN) groups. Values are means ± SE for eight or nine experiments. *P < 0.05 vs. control period; #P < 0.05 vs. glucosamine or Intralipid alone.
- FIG. 3.
Effects of Intralipid and/or glucosamine infusions on insulin-stimulated Rd (A) and skeletal muscle UDP-GlcNAc concentrations (B), measured at the end of the 330-min infusion of saline, Intralipid (IL), glucosamine (GN), or Intralipid and glucosamine. A: Values are means ± SE for eight or nine experiments. B: Data are expressed as percent of control (saline) values to combine the data from different types of muscles (Table 1). *P < 0.05 vs. saline; #P < 0.05 vs. glucosamine or Intralipid alone.
- FIG. 4.
Effects of short (50 and 180 min) Intralipid infusions on skeletal muscle (tibialis anterior) HBP product concentrations. Intralipid infusion was initiated after the 150-min control clamp period, and “0 min” refers to muscles collected at the end of the control period. Values are means ± SE for five experiments.
Tables
- TABLE 1
In this Issue
